SeaStar Medical (ICU) Expected to Announce Quarterly Earnings on Thursday

SeaStar Medical (NASDAQ:ICU) is expected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect SeaStar Medical to post earnings of ($0.97) per share and revenue of $0.2220 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

SeaStar Medical Stock Performance

ICU stock opened at $2.35 on Thursday. The company has a market capitalization of $8.91 million, a PE ratio of -0.14 and a beta of -1.04. SeaStar Medical has a one year low of $2.20 and a one year high of $25.70. The company’s 50 day moving average price is $2.49 and its two-hundred day moving average price is $4.32.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ICU shares. Wall Street Zen raised shares of SeaStar Medical to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, January 22nd. Finally, Maxim Group set a $6.00 price objective on SeaStar Medical in a research note on Thursday, February 12th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell” and a consensus price target of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in SeaStar Medical in the 4th quarter worth $30,000. Millennium Management LLC bought a new position in shares of SeaStar Medical during the third quarter valued at about $102,000. Finally, XTX Topco Ltd raised its stake in shares of SeaStar Medical by 395.4% during the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after acquiring an additional 48,674 shares during the last quarter. 1.69% of the stock is owned by hedge funds and other institutional investors.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.